Medtech Go-To-Market: A Founder'S Device GTM Playbook

Medtech go to market is different from software or biotech because commercialization is gated by three things outside your control: your FDA pathway, hospital procurement, and reimbursement. Before a single device sells, you must align clinical evidence, payer coverage, and a buying committee that rarely includes the clinician who wants it.

Key Takeaways

• Medtech GTM is gated by FDA pathway, hospital procurement, and reimbursement - not just product-market fit.
• The buyer is rarely the user: clinicians champion, but value analysis, supply chain, and finance approve.
• Your FDA pathway (510(k), De Novo, or PMA) sets the earliest possible revenue date and shapes evidence needs.
• Reimbursement via CPT coding and payer coverage often decides whether a hospital can even buy you.
• Clinical evidence is a marketing asset, not just a regulatory one - it moves every buyer role.

What Makes Go-To-Market Different for Medtech Startups?

Most startup GTM playbooks assume a short cycle, a single buyer, and a product you can ship the day it works. Medtech breaks all three assumptions. You cannot sell a device the moment it functions; you must first clear or approve it through the FDA, then convince a hospital system that it is worth the administrative and financial friction of adopting. The "market" is not an open field of willing buyers - it is a small set of concentrated customers (IDNs, GPOs, ASCs) with formal purchasing machinery.

Compounding this, the people who benefit from your device are almost never the people who authorize the purchase. A surgeon may love your tool, but a value analysis committee, a supply chain manager, and a CFO must sign off. Each weighs different proof. That means your marketing and sales motion has to produce evidence for several audiences at once, and it has to run in parallel with regulatory and reimbursement work rather than after it. This is why founders who treat general startup GTM strategy as a template often stall: the medtech version has more gates and longer corridors.

Who Actually Buys a Medical Device and How Do They Decide?

The decision is made by a committee, and your job is to arm every member with what they need to say yes. A clinician champions the device based on patient outcomes and workflow fit. A value analysis committee (VAC) evaluates clinical benefit, cost, and disruption to current practice. Supply chain assesses contract terms, standardization, and whether you fit existing vendor structures. Finance weighs margin, capital versus consumable models, and budget impact. No single role can push a purchase through alone.

Understanding this table is the core of medtech commercialization. A founder who only courts the champion will collect enthusiastic letters of support and zero purchase orders. The motion that works builds a dossier that travels with the champion into the VAC and out to finance.

How Does Your FDA Pathway Shape the GTM Timeline?

Your regulatory pathway is the single biggest determinant of when revenue is even possible. A 510(k) clearance, which shows substantial equivalence to a predicate device, is generally the fastest route and is common for lower-risk devices. A De Novo classification applies when there is no predicate and the device is low-to-moderate risk, establishing a new regulatory class. A PMA (pre-market approval) is reserved for high-risk devices and requires clinical trial evidence, making it the longest and most expensive path.

The pathway dictates both the evidence burden and the credible launch story. A PMA device arrives with a clinical trial already completed - a powerful sales asset. A 510(k) device may need to generate real-world evidence post-launch to win skeptical committees. Founders should map the regulatory milestone dates onto the commercial plan: the day you submit is not the day you sell, and the gap between them is where most GTM budgets are spent.

Why Does Reimbursement Decide Whether Your GTM Works?

A hospital will not buy a device it cannot get paid for. In the US, reimbursement flows through CPT coding (how a procedure or service is billed), payer coverage (whether insurers pay), and the payer mix of the adopting facility. If your device has no assigned code, uncertain coverage, or only works for cash-pay or out-of-network patients, the CFO's answer is no regardless of clinical enthusiasm.

This is why reimbursement strategy is a GTM function, not a back-office task. Founders should identify the relevant CPT codes, understand whether the device is bundled into a payment or separately payable, and model coverage across Medicare, Medicaid, and commercial payers. A clear reimbursement pathway turns a clinical win into a financial one and is often the deciding factor in a value analysis decision.

Which GTM Motion Fits Your Device: Direct Rep, Distributor, or Embedded?

Medtech sells through three common motions. A direct rep model uses your own clinical specialists to drive adoption - expensive but gives control, learning, and margin, and suits novel or high-complexity devices. A distributor or dealer model leverages established relationships and existing hospital contracts, trading margin and message control for speed and reach, which suits commoditized or geographically scattered markets. An embedded or partnership model integrates your device into a larger system or platform, riding another company's commercial engine.

Early-stage founders often start rep-less or with a handful of contract reps to prove the model, then build direct fleets as volume justifies it. The right answer depends on deal complexity, margin, and how much clinical education the market needs. A device that requires workflow change usually needs reps; a drop-in consumable may not.

What Marketing Channels Actually Generate Medtech Pipeline?

Paid social and classic SaaS demand-gen barely move medtech procurement. The channels that work are relationship- and evidence-driven. KOL engagement and society conference presence build the clinical credibility that champions cite in VAC meetings. Peer-reviewed publications and real-world evidence turn your science into a sales asset. Field reps and targeted account-based outreach reach the actual decision units inside IDNs.

Digital health and lighter software-led tools can use content and SEO to build awareness, and the lines between medtech and healthtech marketing strategy blur for software-as-a-medical-device products. But for physical devices, the marketing engine is less about lead volume and more about equipping a small set of high-value accounts with defensible proof. Trade shows, advisory boards, and clinical advisory input are marketing spend, not just networking.

What Is a Step-By-Step Pre-Revenue Medtech GTM Playbook?

Before a first commercial contract exists, the work is sequencing evidence, access, and demand so each unlocks the next. Run these steps in order.

1. Fix the clinical and economic claim. Write the single sentence a clinician and a finance reviewer would both accept, then check that your regulatory pathway and cleared indications actually support it.
2. Build the evidence package. Pair the regulatory submission data with health-economic modeling and, where possible, an early clinical or workflow study a hospital committee can read.
3. Recruit clinical champions. Identify five to ten physicians who own the workflow you change, give them hands-on access, and co-author or co-present the early data.
4. Map reimbursement and coding. Establish whether an existing code covers the procedure, whether the device is bundled into a payment, or whether a new code or coverage decision is required, then plan the timeline around that answer.
5. Run reference sites, not pilots-for-pilots. Choose two or three accounts willing to publish outcomes and to speak to peers, and define in writing what conversion to a paid contract looks like.
6. Standardize the value analysis packet. Assemble the clinical evidence, budget-impact model, integration and service plan, and GPO or contract path into one repeatable submission you can send to every next account.

How Should Medtech Founders Measure GTM Progress Before Revenue?

Because the sales cycle is long, you need leading indicators that precede revenue. Track number of VAC submissions, number of active clinical evaluations or trials, KOL commitments, conference engagements, payer coverage determinations secured, and pipeline of IDN accounts in active conversation. These are the signals that the motion is working before a purchase order appears.

Also watch evidence velocity: publications submitted, data abstracts accepted, and real-world data collected. In medtech, evidence is inventory. A founder who can show a growing body of proof and a widening set of committed advocates is on a real GTM trajectory even with zero booked revenue.

Frequently Asked Questions

How Long Is a Typical Medtech Sales Cycle?

Medtech sales cycles commonly run from several months to over a year, longer than most software deals. The clock starts after regulatory clearance and includes value analysis review, contract and GPO negotiation, IT and supply chain integration, and clinician training. High-complexity or high-cost devices inside large IDNs tend toward the long end, while lower-risk consumables with existing codes can move faster once a champion is engaged.

Do Medtech Startups Need Reimbursement Before They Can Sell?

Not strictly before the first sale, but reimbursement clarity is usually required before hospitals will commit at scale. A single cash-pay or research-use purchase may happen without it, but broad adoption depends on payers covering the procedure and a workable CPT coding and payment pathway. Founders should treat reimbursement as a gating workstream running in parallel with sales, not a task deferred until after the first deal.

How Is Medtech GTM Different from Biotech GTM?

Medtech sells devices and diagnostics directly into hospitals and clinics through procurement and reimbursement, with clinicians championing adoption. Biotech develops therapeutics that typically reach patients through pharma partnership, licensing, or commercial launch after FDA approval, with a very different payer and distribution model. Medtech's buyer is a hospital committee; biotech's path is more often a partner or a payer-negotiated drug channel. The evidence and sales motions barely overlap.

Should an Early Medtech Startup Hire Reps or Use Distributors?

It depends on device complexity, margin, and market education needs. Very early, many founders use a few contract reps or sell founder-led to learn the buying process and refine the message. Distributors offer speed and existing contracts but dilute margin and control. As volume and proof grow, building a direct rep fleet gives control over the clinical story. The pragmatic path is start lean, prove the motion, then choose the model that fits the evidence you can show.